Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CLZ-2002 · 1 trial · 1 indication
Frequency and percentage of treatment-emergent adverse events (TEAEs) and serious adverse events after injection through laboratory tests, physical examinations, vital signs, and electrocardiogram measurements conducted during the clinical trial.
| Arm | Type | Description |
|---|---|---|
| CLZ-2002 | EXPERIMENTAL | CLZ-2002 injection is intramuscular in lower limbs on Day 1. |
| Name | Type | Description |
|---|---|---|
| CLZ-2002 | DRUG | Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells) |
Inclusion Criteria: * Subjects aged 18 years or older * Subjects with a proven diagnosis of Charcot-Marie-Tooth disease type 1 at the time of screening visit * Subjects who have muscle weakness in at least foot dorsiflexion (clinical assessment) at the time of screening visit * Subjects with a CMT ...
CLZ-2002 is an investigational small molecule being developed for the treatment of Charcot Marie Tooth Disease, Type 1. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CLZ-2002 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The drug is in Phase 1 clinical development for Charcot Marie Tooth Disease, Type 1.
CLZ-2002 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not received regulatory approval for any indication.
CLZ-2002 has one completed Phase 1 clinical trial, identified as NCT05947578, titled "The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease." The trial enrolled 9 participants in South Korea and was not randomized or blinded.
CLZ-2002 is not FDA approved. It is an investigational drug in Phase 1 clinical development for Charcot Marie Tooth Disease, Type 1. The completed Phase 1 trial focused on safety and tolerability.